CTOs on the Move

Adagio Therapeutics

www.adagiotx.com

 
Adagio Therapeutics, Inc` is a clinical-stage a biotechnology company developing best-in-class antibodies that can broadly neutralize SARS-CoV-2, SARS-CoV-1 and additional pre-emergent coronaviruses` Our candidates are optimized using Adimab’s industry-leading antibody engineering capabilities and are designed to provide patients and clinicians with an unsurpassed combination of potency, breadth, durable protection (via half-life extension), manufacturability, tolerability, and affordability` Our portfolio of SARS-CoV-2 antibodies includes multiple, non-competing antibodies with distinct binding epitopes` Pre-clinical data show that our lead antibody ADG20 matches or exceeds the potency and coverage of other clinical SARS-CoV-2 antibody programs` We plan to advance ADG20 aggressively through global clinical trials ...
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.adagiotx.com
  • 303 Wyman Street Suite 300
    Waltham, MA USA 02451
  • Phone: 781.819.0080

Executives

Name Title Contact Details

Funding

Adagio Therapeutics raised $50M on 07/16/2020
Adagio Therapeutics raised $80M on 11/10/2020
Adagio Therapeutics raised $336M on 04/19/2021

Similar Companies

JPT Peptide Technologies GmbH

JPT Peptide Technologies GmbH is a Acton, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Arnold A Welu Dental Laboratory

Arnold A Welu Dental Laboratory, Inc is a Fargo, ND-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Zija International

Zija International is a Lindon, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Induchem Usa

Induchem Usa is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Tyme

TYME, Inc. is a pharmaceutical company focused on creating medicines that specialize in using the body’s immune system to treat diseases. The body has the ability to fight off major diseases and heal itself. Tyme is researching a mechanism that it believes may work alongside the body’s immune system to fight Stage IV Metastatic Cancer. Tyme hopes to provide a novel compound for physicians to use in a treatment regimen for patients fighting six major cancers (breast, lung, prostrate, gastric, esophageal and pancreatic cancers) responsible for 62% of the annual cancer deaths in the United States. The SM-88, Tyme’s proprietary compound, is a novel compound that has the potential to alter defenses to oxidative stress and increase free radical availability to the cancer cell. SM-88 is designed to penetrate the living cancer cells and introduce multiple mechanisms to kill the cell. Inducing transfer of electrons in the cancer cells may allow catalyzed external free radicals to react and stress the cell. SM-88 is a combination of low dose agents used for non-cancer treatment.